KROS: Keros Therapeutics, Inc.
About
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.
Current Value
$53.531 Year Return
Current Value
$53.531 Year Return
Key Details
Market Cap
$2.17B
P/E Ratio
-10.3
1Y Stock Return
73.87%
1Y Revenue Growth
8037.50%
Dividend Yield
0.00%
Price to Book
4.0
Strategies that include KROS
Stock's related to KROS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KYMR | 47.28% | $2.77B | +125.95% | 0.00% |
| AKRO | 44.51% | $2.17B | +93.09% | 0.00% |
| PLRX | 43.79% | $778.32M | -9.55% | 0.00% |
| VRDN | 40.52% | $1.60B | +28.92% | 0.00% |
| DAWN | 39.75% | $1.36B | +13.42% | 0.00% |
| XNCR | 39.68% | $1.65B | +27.73% | 0.00% |
| PGEN | 39.47% | $228.91M | -28.00% | 0.00% |
| ENTA | 39.46% | $199.60M | -5.52% | 0.00% |
| ALEC | 38.99% | $377.04M | -19.46% | 0.00% |
| CWH | 38.69% | $1.36B | +5.90% | 2.22% |
| BEAM | 38.29% | $2.09B | -9.52% | 0.00% |
| VIR | 38.09% | $954.40M | -26.51% | 0.00% |
| QS | 38.08% | $2.54B | -13.31% | 0.00% |
| ALLO | 38.02% | $444.50M | -24.82% | 0.00% |
| ABCL | 37.97% | $800.44M | -37.56% | 0.00% |
| COGT | 37.89% | $1.00B | +31.69% | 0.00% |
| BZH | 37.63% | $1.02B | +22.71% | 0.00% |
| PDSB | 37.50% | $78.37M | -66.59% | 0.00% |
| RXRX | 37.26% | $1.80B | -4.13% | 0.00% |
| ARWR | 36.81% | $2.31B | -34.44% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SNY | <0.01% | $120.34B | +3.11% | 4.25% |
| HRL | -<0.01% | $16.30B | -8.38% | 3.81% |
| RTX | 0.03% | $158.34B | +52.22% | 2.09% |
| CLMT | -0.05% | $1.79B | +35.14% | 0.00% |
| CPSH | 0.06% | $20.70M | -40.13% | 0.00% |
| LRN | 0.07% | $4.43B | +74.97% | 0.00% |
| CHKP | -0.07% | $19.20B | +20.74% | 0.00% |
| ARQ | -0.11% | $332.89M | +216.80% | 0.00% |
| NAPA | 0.14% | $1.63B | +9.61% | 0.00% |
| PEG | -0.15% | $44.89B | +40.46% | 2.63% |
| VERX | -0.17% | $7.99B | +89.70% | 0.00% |
| KDP | -0.18% | $42.76B | -1.22% | 2.77% |
| WTTR | -0.19% | $1.45B | +92.87% | 1.78% |
| HQY | -0.19% | $8.97B | +52.15% | 0.00% |
| VET | -0.19% | $1.57B | -21.53% | 3.35% |
| NERV | 0.20% | $14.69M | -58.00% | 0.00% |
| STNG | -0.20% | $2.96B | +0.87% | 2.75% |
| GPRK | 0.26% | $440.00M | -9.95% | 6.37% |
| PAC | -0.28% | $8.16B | +31.59% | 0.00% |
| AVAL | -0.32% | $791.37M | -4.11% | 7.14% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CI | -15.92% | $89.70B | +12.57% | 1.68% |
| NOC | -13.30% | $71.54B | +4.23% | 1.60% |
| HUSA | -12.57% | $16.69M | -11.56% | 0.00% |
| PULM | -11.84% | $19.83M | +202.98% | 0.00% |
| PGR | -11.56% | $149.10B | +57.29% | 0.45% |
| GIS | -11.46% | $34.85B | -2.91% | 3.78% |
| CPB | -10.41% | $12.96B | +7.08% | 3.40% |
| DMLP | -10.36% | $1.58B | +18.00% | 10.54% |
| MCK | -10.28% | $78.15B | +35.51% | 0.42% |
| ACGL | -9.81% | $36.00B | +16.84% | 0.00% |
| LMT | -9.66% | $126.40B | +18.99% | 2.36% |
| LITB | -9.21% | $35.48M | -75.45% | 0.00% |
| COP | -8.58% | $130.16B | -1.63% | 2.59% |
| SCKT | -8.40% | $10.88M | +15.32% | 0.00% |
| K | -8.39% | $27.77B | +52.50% | 2.79% |
| SHEL | -7.54% | $205.19B | -1.07% | 4.20% |
| CME | -7.46% | $82.76B | +9.21% | 1.98% |
| SEG | -7.28% | $319.72M | +12.41% | 0.00% |
| AJG | -7.19% | $64.17B | +17.51% | 0.80% |
| VIST | -7.08% | $4.75B | +67.10% | 0.00% |
ETF's related to KROS
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 54.24% | $6.58B | 0.35% |
| IBB | 47.59% | $6.66B | 0.45% |
| PTH | 47.34% | $143.31M | 0.6% |
| GNOM | 46.98% | $70.59M | 0.5% |
| ARKG | 46.31% | $1.13B | 0.75% |
| IWC | 46.15% | $933.99M | 0.6% |
| XPH | 44.27% | $157.87M | 0.35% |
| IWO | 43.38% | $12.56B | 0.24% |
| PBE | 42.28% | $258.53M | 0.58% |
| VTWO | 41.73% | $12.38B | 0.1% |
| IWM | 41.66% | $75.73B | 0.19% |
| FBT | 41.36% | $1.11B | 0.56% |
| RSPA | 41.15% | $273.87M | 0% |
| NUSC | 40.60% | $1.27B | 0.31% |
| KOMP | 40.44% | $2.09B | 0.2% |
| ESML | 40.10% | $1.90B | 0.17% |
| XHE | 39.94% | $213.41M | 0.35% |
| PINK | 39.86% | $161.15M | 0.5% |
| KBWD | 39.80% | $397.36M | 2.02% |
| SMMD | 39.53% | $1.24B | 0.15% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -36.60% | $388.04M | 1.43% |
| VIXY | -16.49% | $195.31M | 0.85% |
| DBE | -15.70% | $50.13M | 0.77% |
| UUP | -15.41% | $309.25M | 0.77% |
| DBO | -14.94% | $217.57M | 0.77% |
| USDU | -14.61% | $201.97M | 0.5% |
| EQLS | -11.45% | $76.08M | 1% |
| KMLM | -11.27% | $353.87M | 0.9% |
| COMT | -10.72% | $829.06M | 0.48% |
| GSG | -10.15% | $914.42M | 0.75% |
| PDBC | -9.26% | $4.40B | 0.59% |
| DBC | -8.92% | $1.39B | 0.87% |
| KRBN | -8.38% | $242.47M | 0.85% |
| CTA | -8.27% | $350.27M | 0.78% |
| MINT | -6.25% | $11.62B | 0.35% |
| KCCA | -5.83% | $220.51M | 0.87% |
| FMF | -5.32% | $244.61M | 0.95% |
| USCI | -3.95% | $185.47M | 1.07% |
| DBMF | -3.09% | $1.02B | 0.85% |
| IXC | -2.72% | $2.20B | 0.41% |
News
Yahoo
Keros Therapeutics ( NASDAQ:KROS ) Third Quarter 2024 Results Key Financial Results Net loss: US$53.0m (loss widened by...
Yahoo
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended September 30, 2024. “This con
Finnhub
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results LEXINGTON, Mass., November 6, 2024 -- Keros Therapeutics, Inc. , a...
Yahoo
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentat
Finnhub
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference LEXINGTON, Mass., November 6, 2024 -- Keros Therapeutics, Inc. , a clinical-stage...
Yahoo
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that three abstracts will be presented from its hematology program at the 66th American Society of Hematology (“ASH”
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.